Breakthroughs in Bladder Cancer: Key Highlights from ASCO GU 2025
Key Takeaways Trial Updates: Antibody-Drug Conjugates (ADCs): Future Outlook: 26 February 2025 ASCO GU 2025
Key Takeaways Trial Updates: Antibody-Drug Conjugates (ADCs): Future Outlook: 26 February 2025 ASCO GU 2025
The U.S. Food and Drug Administration (FDA) has approved Amgen’s combination therapy of Lumakras (sotorasib)
The FDA has approved Grafapex (treosulfan) in combination with fludarabine as a conditioning regimen for
Key Highlights: Clinical Trial Findings: DESTINY-Breast06 The FDA’s decision was based on results from the
Explore the latest innovations in cancer treatment that are shaping the future of oncology.
CMG901 shows promise in treating advanced gastric and GEJ cancers, with a manageable safety profile
CAR-NK therapy offers a safer, more accessible alternative to CAR-T, using off-the-shelf natural killer cells
ctDNA testing predicts lung cancer relapse, enabling personalized treatment and better outcomes.